Decreased Appetite: Many users notice a reduction in hunger, which can aid in weight loss
Mimic satiety hormones Some peptides, such as GLP-1 agonists (glucagon-like peptide 1), mimic the activity of natural hormones, which help regulate hunger and digestion
Weight gain is a complex process rather than the result of a single vitamin excess, and it depends on a combination of many factors: Nutritional Habits: Your daily calorie intake is the most fundamental cause of weight gain
That said, correcting a genuine B12 deficiency may indirectly support weight management efforts
Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome
